AIDS TREATMENT NEWS Issue #78, May 5, 1989
John S. James
What will be the practical effect of these approvals of drugs which have already been available under a variety of arrangements?
For aerosol pentamidine, full approval will help with insurance reimbursement. Until now, some insurance companies and government agencies have refused to pay for the treatment, claiming that it was "experimental". Others have paid, since the cost of preventing pneumocystis with aerosol pentamidine is far less than the cost of treating it in a hospital. It is widely suspected that companies which refused to pay have calculated that they could save money in the long run by having their clients die.
For ganciclovir, approval will allow the manufacturer to charge for the drug, currently provided free under a treatment IND. We do not know what the price will be. Insurance presumably will pay since the drug will be approved, but many do not have insurance, or do not have policies which cover prescription drugs.
One advantage of the approval is that physicians will be allowed to use ganciclovir to treat CMV infection in the intestines or elsewhere besides the retina, even though the FDA approval will not specifically cover such use. Physicians may be reluctant to prescribe for such "unlabeled" uses, however, and insurance companies may refuse to pay.
Another advantage of the approval of ganciclovir is that it will now become possible to conduct a trial to compare this drug directly with foscarnet for treating CMV retinitis, a trial specifically recommended by the advisory committee. Until now such a trial has been blocked by the prohibition against using more than one "experimental" drug in the same study.
890505
ATN07803
Copyright © 1989 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .